Health
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person – Manchestertimes
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 23, 2020–
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved…
-
Noosa News24 hours agoThis 42-Kilometre Walking Trail on the NSW North Coast Weaves Through Ancient Rainforest, Volcanic Mountains and Spectacular Waterfalls
-
Noosa News22 hours agoEaster weather forecast: What to expect in Sydney, Perth, Melbourne, Brisbane, Adelaide and Canberra
-
Noosa News22 hours agoQueensland cop cleared by court of stealing watches during anti-gang raid
-
Noosa News23 hours agoAnother power station confirmed offline as political fallout continues amid cultural issues